// App-Quantinova.ai

1224 : Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials

Researchers

Presenter

  • Stephane Ferretti

Principal Investigators

  • Ramona Rebmann

  • Marjorie Berger

  • Francesca Santacroce

  • Genevieve Albrecht

  • Kerstin Pollehn

  • Dario Sterker

  • Markus Wartmann

  • Andreas Hueber

  • Marion Wiesmann

  • Michael R. Jensen

  • Francesco Hofmann

  • William R. Sellers

  • Philipp Holzer

  • Sebastien Jeay

Medical Centers

  • Novartis Institutes for BioMedical Research, Basel, Switzerland

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • BCL2 Binding Component 3

Drug/Treatment

  • HDM 201

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved